Dutch biotech developing antibody treatments for autoimmune diseases (CALY-002).
Founders
Alain Vicari(France · ♂)— A translational immunologist who led immunology at Merck Serono, he co-founded Calypso in 2013 as a spin-out when Merck closed its Geneva site, advancing an anti-IL-15 antibody for autoimmune disease (later acquired by Novartis).
Yolande Chvatchko(France · ♀)— A translational immunology researcher from Merck Serono, she co-founded Calypso in 2013 as Chief Scientific Officer to develop its anti-IL-15 monoclonal antibody for chronic autoimmune conditions.
Team & hubs
In the network
Shares the most investors with (number = shared investors):